An 8-month-old boy was diagnosed with visceral leishmaniasis in the Ukraine, a non-endemic area. His mother had been treated for visceral leishmaniasis at 28-32 weeks gestation whilst working in Alicante, Spain and delivered her infant at 38 weeks gestation by elective caesarean section in Ukraine. It is presumed that the infant's infection was as a result of vertical transmission.
Medical records and incidence data were analyzed retrospectively to document the epidemiology, clinical features, and outcomes of mumps in relation to vaccination status in the Lviv province of Ukraine over a 7.5-year period, beginning in 2000, when a second dose of mumps vaccine was introduced. Lviv, 1 of 27 provinces in western Ukraine, with a land area of 21,833 km(2), had a total population of about 2,555,834 in 2006. The initial success of the second dose introduction in 2000 in Ukraine was limited by a local outbreak of mumps in Lviv province in 2000-2002 due to a vaccine shortage; most cases were over the age of 7 years. The vaccine with the Leningrad-3 virus strain used before 2001 was then replaced by the triple vaccine "Priorix", with the RIT 4385 derivate of the Jeryl Lynn strain, Belgium. Orchitis and aseptic meningitis were associated with the Russian vaccine. Of the 10,894 reported cases, the most severe (367 cases, 3.4%) were hospitalized in the Lviv Hospital for Infectious Diseases. Admitted patients were predominantly male and over 14 years old. Of the 367 patients admitted to the Lviv Hospital for Infectious Diseases, 45.8% had been vaccinated (mostly by a first dose of Russian vaccine), 15.9% had not been vaccinated, and 38.1% had an unknown vaccination status. More mumps cases occurred in winter and spring than in summer and autumn. The clinical picture and complications (orchitis, pancreatitis, meningitis, and encephalitis) were typical of this disease. The vaccine shortage and an increase in the susceptible population among those who received the Russian vaccine contributed to the outbreak. The use of vaccine with a derivate of the Jeryl Lynn strain has resulted in a dramatic drop in mumps cases since 2002.
Aseptic meningitis is one of the most common inflammatory disorders of the meninges of the central nervous system (CNS). The aim of our study was to investigate the cytokine profiles in the CSF and in the serum of children with aseptic meningitis to determine their role in CNS inflammation. Sixty-eight (68) children were kept under observation. Cytokine profile of CSF and blood (based on the results of determining of IL-1β, IL-4, IL-10, TNF-α levels) and procalcitonin in children were revealed, meningitis severity were estimated by AMSS score. It was found that in the majority of patients with aseptic meningitis, the levels of IL-1β, TNF-α, IL-10 in CSF were increased and exceeded the serum cytokines levels. The severe course of meningitis was characterized by significantly higher concentrations of IL-1β and TNF-α in CSF, which was confirmed by positive correlation between AMSS score and IL-1β concentration (r=0.46, p<0.01), IL-10 (r=0.32, p<0.01), TNF-α (r=0.62, p<0.05). The IL-10/TNF-α ratio was – 17.8. PCT level in CSF was within normal limits in the majority of patients with meningitis. Increasing of anti-inflammatory cytokine levels in aseptic meningitis contributes to preventing of excessive inflammatory/immune responses in the brain. This can cause a longer diseases course and a longer recovery period. This can an indicate active production of cytokines in the central nervous system due to intrathecal inflammation and activation of immune responses caused by viral infection, but not due to penetration across the blood-brain barrier.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.